Literature DB >> 27238974

Effects of nicotine in combination with drugs described as positive allosteric nicotinic acetylcholine receptor modulators in vitro: discriminative stimulus and hypothermic effects in mice.

Megan J Moerke1, Fernando B de Moura1, Wouter Koek2, Lance R McMahon3.   

Abstract

Some drugs that are positive allosteric nAChR modulators in vitro, desformylflustrabromine (dFBr), PNU-120596 and LY 2087101, have not been fully characterized in vivo. These drugs were examined for their capacity to share or modify the hypothermic and discriminative stimulus effects of nicotine (1mg/kg s.c.) in male C57Bl/6J mice. Nicotine, dFBr, and PNU-120596 produced significant hypothermia, whereas LY 2087101 (up to 100mg/kg) did not. Nicotine dose-dependently increased nicotine-appropriate responding and decreased response rate; the respective ED50 values were 0.56mg/kg and 0.91mg/kg. The modulators produced no more than 38% nicotine-appropriate responding up to doses that disrupted operant responding. Rank order potency was the same for hypothermia and rate-decreasing effects: nicotine>dFBr>PNU-120596=LY 2087101. Mecamylamine and the α4β2 nAChR antagonist dihydro-β-erythroidine, but not the α7 antagonist methyllycaconitine, antagonized the hypothermic effects of nicotine. In contrast, mecamylamine did not antagonize the hypothermic effects of the modulators. The combined discriminative stimulus effects of DFBr and nicotine were synergistic, whereas the combined hypothermic effects of nicotine with either dFBr or PNU-120596 were infra-additive. PNU-120596 did not modify the nicotine discriminative stimulus, and LY 2087101 did not significantly modify either effect of nicotine. Positive modulation of nicotine at nAChRs by PNU-120596 and LY 2087101 in vitro does not appear to confer enhancement of the nAChR-mediated hypothermic or discriminative stimulus effects of nicotine. However, dFBr appears to be a positive allosteric modulator of some behavioral effects of nicotine at doses of dFBr smaller than the doses producing unwanted effects (e.g. hypothermia) through non-nAChR mechanisms.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Additivity; Drug discrimination; Hypothermia; Nicotinic acetylcholine receptor; Positive allosteric modulator; Synergy

Mesh:

Substances:

Year:  2016        PMID: 27238974      PMCID: PMC4980200          DOI: 10.1016/j.ejphar.2016.05.032

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  33 in total

Review 1.  α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.

Authors:  Maryka Quik; Susan Wonnacott
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

2.  A novel positive allosteric modulator of the alpha7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization.

Authors:  Raymond S Hurst; Mihaly Hajós; Mario Raggenbass; Theron M Wall; Nicole R Higdon; Judy A Lawson; Karen L Rutherford-Root; Mitchell B Berkenpas; W E Hoffmann; David W Piotrowski; Vincent E Groppi; Geraldine Allaman; Roch Ogier; Sonia Bertrand; Daniel Bertrand; Stephen P Arneric
Journal:  J Neurosci       Date:  2005-04-27       Impact factor: 6.167

Review 3.  Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: advantages and limitations.

Authors:  Dustin K Williams; Jingyi Wang; Roger L Papke
Journal:  Biochem Pharmacol       Date:  2011-05-14       Impact factor: 5.858

Review 4.  Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia.

Authors:  Jared W Young; Mark A Geyer
Journal:  Biochem Pharmacol       Date:  2013-07-12       Impact factor: 5.858

5.  Antagonism of the discriminative and aversive stimulus properties of nicotine in C57BL/6J mice.

Authors:  J Gommans; I P Stolerman; M Shoaib
Journal:  Neuropharmacology       Date:  2000-10       Impact factor: 5.250

6.  The role of nicotinic receptor beta-2 subunits in nicotine discrimination and conditioned taste aversion.

Authors:  M Shoaib; J Gommans; A Morley; I P Stolerman; R Grailhe; J-P Changeux
Journal:  Neuropharmacology       Date:  2002-03       Impact factor: 5.250

7.  Evidence that nicotine can acutely desensitize central nicotinic acetylcholinergic receptors.

Authors:  J R James; H F Villanueva; J H Johnson; S Arezo; J A Rosecrans
Journal:  Psychopharmacology (Berl)       Date:  1994-04       Impact factor: 4.530

Review 8.  The scientific case that nicotine is addictive.

Authors:  I P Stolerman; M J Jarvis
Journal:  Psychopharmacology (Berl)       Date:  1995-01       Impact factor: 4.530

9.  The antinociceptive effects of nicotinic receptors α7-positive allosteric modulators in murine acute and tonic pain models.

Authors:  Kelen Freitas; F Ivy Carroll; M Imad Damaj
Journal:  J Pharmacol Exp Ther       Date:  2012-10-31       Impact factor: 4.030

Review 10.  The therapeutic promise of positive allosteric modulation of nicotinic receptors.

Authors:  Victor V Uteshev
Journal:  Eur J Pharmacol       Date:  2014-02-12       Impact factor: 4.432

View more
  7 in total

1.  Differential cross-tolerance to the effects of nicotinic acetylcholine receptor drugs in C57BL/6J mice following chronic varenicline.

Authors:  Fernando B de Moura; Lance R McMahon
Journal:  Behav Pharmacol       Date:  2019-08       Impact factor: 2.293

2.  Nicotine-like discriminative stimulus effects of acetylcholinesterase inhibitors and a muscarinic receptor agonist in Rhesus monkeys.

Authors:  Megan J Moerke; Lance R McMahon
Journal:  Drug Dev Ind Pharm       Date:  2019-02-22       Impact factor: 3.225

3.  Reversal of Nicotine Withdrawal Signs Through Positive Allosteric Modulation of α4β2 Nicotinic Acetylcholine Receptors in Male Mice.

Authors:  Ayman K Hamouda; Asti Jackson; Deniz Bagdas; M Imad Damaj
Journal:  Nicotine Tob Res       Date:  2018-06-07       Impact factor: 4.244

Review 4.  More than Smoke and Patches: The Quest for Pharmacotherapies to Treat Tobacco Use Disorder.

Authors:  M J Moerke; L R McMahon; J L Wilkerson
Journal:  Pharmacol Rev       Date:  2020-04       Impact factor: 25.468

5.  Potentiation of (α4)2(β2)3, but not (α4)3(β2)2, nicotinic acetylcholine receptors reduces nicotine self-administration and withdrawal symptoms.

Authors:  Ayman K Hamouda; Malia R Bautista; Lois S Akinola; Yasmin Alkhlaif; Asti Jackson; Moriah Carper; Wisam B Toma; Sumanta Garai; Yen-Chu Chen; Ganesh A Thakur; Christie D Fowler; M Imad Damaj
Journal:  Neuropharmacology       Date:  2021-04-18       Impact factor: 5.273

6.  Examining the Effects of (α4)3(β2)2 Nicotinic Acetylcholine Receptor-Selective Positive Allosteric Modulator on Acute Thermal Nociception in Rats.

Authors:  Farah Deba; Kara Ramos; Matthew Vannoy; Kemburli Munoz; Lois S Akinola; M Imad Damaj; Ayman K Hamouda
Journal:  Molecules       Date:  2020-06-25       Impact factor: 4.411

7.  Effect of imidacloprid ingestion on immune responses to porcine reproductive and respiratory syndrome virus.

Authors:  J Hernandez; A Volland; B J Leyshon; M Juda; J M Ridlon; R W Johnson; A J Steelman
Journal:  Sci Rep       Date:  2018-08-02       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.